SCHEMBL119469

SCHEMBL119469

O=S(=O)(NCc1ccccc1)c1ccc(Br)cc1F

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.66
LMNA P02545 3/20 0.62
CA12 O43570 2/20 0.53
CA9 Q16790 2/20 0.53
MAPT P10636 3/20 0.52
KDM4E B2RXH2 1/20 0.52
MAPK1 P28482 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
TP53 P04637 2/20 0.50
KEAP1 Q14145 1/20 0.50
CYP19A1 P11511 1/20 0.50
SLC12A2 P55011 1/20 0.50
SLC12A5 Q9H2X9 1/20 0.50
CYP1A2 P05177 1/20 0.49
CYP2C19 P33261 1/20 0.49
CNR1 P21554 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31113886 0.88 KMT2A (0.62) KMT2ALMNACA12CA9MAPT
SCHEMBL31113865 0.82 KMT2A (0.66) KMT2ALMNACA12CA9MAPT
SCHEMBL120177 0.82 LMNA (0.66) KMT2ALMNACA12CA9MAPT
SCHEMBL16568639 0.81 LMNA (0.68) KMT2ALMNACA12CA9MAPT
SCHEMBL119909 0.79 LMNA (0.77) KMT2ALMNACA12CA9MAPT
SCHEMBL15758655 0.78 CNR1 (0.44) KMT2ALMNACA12CA9MAPT
SCHEMBL3022066 0.77 CNR2 (0.48) CNR1
SCHEMBL31113449 0.76 ALDH1A1 (0.74) LMNAMAPTSMN1; SMN2CYP1A2CYP2C19
SCHEMBL119541 0.76 SMN1; SMN2 (0.54) KMT2ALMNACA12CA9MAPT
SCHEMBL3255593 0.76 KDM4E (0.46) KMT2ALMNAKDM4ECYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102427810-A Sulfamoylbenzoic acid derivatives as TRPM8 antagonists RAQUALIA PHARMA INC 2012-04-25 CN disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
EP-2424517-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RaQualia Pharma Inc (JP) 2012-03-07 EP disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 KMT2A 941/4885LMNA 3339/4885CA12 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.